These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 26866639)

  • 1. Androgens in polycystic ovary syndrome: lessons from experimental models.
    Walters KA
    Curr Opin Endocrinol Diabetes Obes; 2016 Jun; 23(3):257-63. PubMed ID: 26866639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen signaling pathways driving reproductive and metabolic phenotypes in a PCOS mouse model.
    Aflatounian A; Edwards MC; Rodriguez Paris V; Bertoldo MJ; Desai R; Gilchrist RB; Ledger WL; Handelsman DJ; Walters KA
    J Endocrinol; 2020 Jun; 245(3):381-395. PubMed ID: 32229702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroendocrine androgen action is a key extraovarian mediator in the development of polycystic ovary syndrome.
    Caldwell ASL; Edwards MC; Desai R; Jimenez M; Gilchrist RB; Handelsman DJ; Walters KA
    Proc Natl Acad Sci U S A; 2017 Apr; 114(16):E3334-E3343. PubMed ID: 28320971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Animal models of hyperandrogenism and ovarian morphology changes as features of polycystic ovary syndrome: a systematic review.
    Paixão L; Ramos RB; Lavarda A; Morsh DM; Spritzer PM
    Reprod Biol Endocrinol; 2017 Feb; 15(1):12. PubMed ID: 28183310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgens and polycystic ovary syndrome.
    Nisenblat V; Norman RJ
    Curr Opin Endocrinol Diabetes Obes; 2009 Jun; 16(3):224-31. PubMed ID: 19390322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen signaling in adipose tissue, but less likely skeletal muscle, mediates development of metabolic traits in a PCOS mouse model.
    Xiong T; Rodriguez Paris V; Edwards MC; Hu Y; Cochran BJ; Rye KA; Ledger WL; Padmanabhan V; Handelsman DJ; Gilchrist RB; Walters KA
    Am J Physiol Endocrinol Metab; 2022 Aug; 323(2):E145-E158. PubMed ID: 35658542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haplosufficient genomic androgen receptor signaling is adequate to protect female mice from induction of polycystic ovary syndrome features by prenatal hyperandrogenization.
    Caldwell AS; Eid S; Kay CR; Jimenez M; McMahon AC; Desai R; Allan CM; Smith JT; Handelsman DJ; Walters KA
    Endocrinology; 2015 Apr; 156(4):1441-52. PubMed ID: 25643156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgens and ovarian function: translation from basic discovery research to clinical impact.
    Walters KA; Rodriguez Paris V; Aflatounian A; Handelsman DJ
    J Endocrinol; 2019 Aug; 242(2):R23-R50. PubMed ID: 31125975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of androgen and its related signals in PCOS.
    Ye W; Xie T; Song Y; Zhou L
    J Cell Mol Med; 2021 Feb; 25(4):1825-1837. PubMed ID: 33369146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of androgens in the ovary.
    Walters KA; Handelsman DJ
    Mol Cell Endocrinol; 2018 Apr; 465():36-47. PubMed ID: 28687450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNAs related to androgen metabolism and polycystic ovary syndrome.
    Sørensen AE; Udesen PB; Wissing ML; Englund ALM; Dalgaard LT
    Chem Biol Interact; 2016 Nov; 259(Pt A):8-16. PubMed ID: 27270454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgens in polycystic ovary syndrome: the role of exercise and diet.
    Giallauria F; Palomba S; Vigorito C; Tafuri MG; Colao A; Lombardi G; Orio F
    Semin Reprod Med; 2009 Jul; 27(4):306-15. PubMed ID: 19530064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen-mediated Perturbation of the Hepatic Circadian System Through Epigenetic Modulation Promotes NAFLD in PCOS Mice.
    Roy S; Abudu A; Salinas I; Sinha N; Cline-Fedewa H; Yaw AM; Qi W; Lydic TA; Takahashi DL; Hennebold JD; Hoffmann HM; Wang J; Sen A
    Endocrinology; 2022 Oct; 163(10):. PubMed ID: 35933634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen excess: a hallmark of polycystic ovary syndrome.
    Wang K; Li Y; Chen Y
    Front Endocrinol (Lausanne); 2023; 14():1273542. PubMed ID: 38152131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Genetic aspects of polycystic ovary syndrome].
    Jakubowski L
    Endokrynol Pol; 2005; 56(3):285-93. PubMed ID: 16350721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review: fetal programming of polycystic ovary syndrome by androgen excess: evidence from experimental, clinical, and genetic association studies.
    Xita N; Tsatsoulis A
    J Clin Endocrinol Metab; 2006 May; 91(5):1660-6. PubMed ID: 16522691
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Yanes Cardozo LL; Romero DG; Reckelhoff JF
    Physiology (Bethesda); 2017 Sep; 32(5):357-366. PubMed ID: 28814496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mouse models to study polycystic ovary syndrome: a possible link between metabolism and ovarian function?
    van Houten EL; Visser JA
    Reprod Biol; 2014 Mar; 14(1):32-43. PubMed ID: 24607253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Mechanism of Androgen Actions in PCOS Etiology.
    Rodriguez Paris V; Bertoldo MJ
    Med Sci (Basel); 2019 Aug; 7(9):. PubMed ID: 31466345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurokinin 3 Receptor Antagonism Ameliorates Key Metabolic Features in a Hyperandrogenic PCOS Mouse Model.
    Sucquart IE; Nagarkar R; Edwards MC; Rodriguez Paris V; Aflatounian A; Bertoldo MJ; Campbell RE; Gilchrist RB; Begg DP; Handelsman DJ; Padmanabhan V; Anderson RA; Walters KA
    Endocrinology; 2021 May; 162(5):. PubMed ID: 33522579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.